In June 2017, Actelion, a Swiss company, became part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Actelion's medicines help expand and strengthen Janssen’s portfolio with leading, differentiated in-market medicines and promising late-stage compounds. Janssen has added Pulmonary Hypertension as a therapeutic area of focus to maintain the leadership position Actelion has built in this important disease area.
In this section, you will find Actelion’s latest media releases.
In this section, you will find the last annual reports that Actelion Ltd published as an independent company. Split into its main components, you will find easy downloads of the 4 main elements of the report in an interactive pdf format, giving you the choice of navigating details on your tablet or computer.
On 16 June 2017, Actelion became part of the Janssen Pharmaceutical Companies of Johnson and Johnson. On the same day, Actelion applied for the de-listing of Actelion shares on the SIX Swiss exchange.
Proposed Transaction JNJ
Publication of Idorsia’s prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange.